Robert Rhee, MD, of the Maimonides Heart and Vascular Institute performed the procedures and led national clinical trials
March 30, 2021, Brooklyn, NY – Maimonides Medical Center announced today that its Vascular Surgery team was among the first in the nation to have successfully performed procedures using a revolutionary new endovascular prosthesis for treatment of high-risk Abdominal Aortic Aneurysms (AAAs) with severe aortic anatomy. The device received regulatory approval for commercial use by the Food and Drug Administration (FDA) in December 2020.
Dr. Robert Rhee, Chief of Vascular Surgery at Maimonides Medical Center and National Principal Investigator for the national clinical device trials, led the team at Maimonides who successfully treated two patients today who were suffering from life-threatening abdominal aortic aneurysms.
“It is incredibly gratifying to see our research and clinical trials lead directly to making this procedure available to patients who previously had extremely limited treatment options,” said Dr. Robert Rhee of Maimonides. “For years, doctors have been asking for better ways to treat high-risk AAA patients with complex anatomies. Now for the first time we have a breakthrough solution that offers new hope to patients and doctors alike.”
In 2017, Dr. Rhee pioneered the first worldwide procedure of the device at Maimonides Medical Center and now has the distinction of being among the first doctors in the nation to do so again after its FDA approval.
“It’s been a privilege leading my fellow clinicians at 50 health systems across the country in this important research over the last eight years and achieving such outstanding results,” Rhee said.
“We are proud that Maimonides Medical Center continues to play an important role in advancing medicine and developing successful, state-of-the-art solutions for some of the most complex medical and surgical challenges. I applaud Dr. Rhee and his team for their leadership in developing the implementation of this transformative new device,” said Kenneth D. Gibbs, President and CEO of Maimonides Medical Center.
According to the Society for Vascular Surgery (Vascular.org), approximately 200,000 people in the U.S. are diagnosed with an abdominal aortic aneurysm (AAA) every year. A ruptured AAA is the 15th leading cause of death in the country, and the 10th leading cause of death in men older than 55.
About the Gore® Excluder® Conformable AAA Endoprosthesis with Active Control System
The Gore® Excluder® conformable device debuts the Gore® Active Control System into the abdominal aorta and is comprised of a conformable stent graft, enhanced device positioning, and optional angulation control. This delivery system is the first to feature angulation control, giving physicians the option to angle the device to achieve orthogonal placement to the aortic blood flow lumen to maximize conformability and seal.
About Maimonides Medical Center
Maimonides Medical Center is a 711-bed non-profit tertiary care provider in Brooklyn, New York. It operates the largest hospital in Brooklyn as well as the borough's only Children’s Hospital and only full-service Cancer Center. Maimonides physicians are nationally known for clinical excellence, innovation and groundbreaking research. An independent teaching and research institution, Maimonides is a major clinical training site for the SUNY Downstate College of Medicine. Founded in 1911, the Medical Center continues to grow and adapt to the needs of Brooklyn's patients and families. Maimonides is an affiliate of Northwell Health. For additional information on the nationally recognized clinical services at Maimonides Medical Center, please visit www.maimo.org.